A
Anthony Nichols
Researcher at Merck Serono
Publications - 17
Citations - 2761
Anthony Nichols is an academic researcher from Merck Serono. The author has contributed to research in topics: ASK1 & MAP kinase kinase kinase. The author has an hindex of 12, co-authored 17 publications receiving 2682 citations.
Papers
More filters
Journal ArticleDOI
Bid-induced Conformational Change of Bax Is Responsible for Mitochondrial Cytochrome c Release during Apoptosis
Solange Desagher,Astrid Osen-Sand,Anthony Nichols,Robert Eskes,Sylvie Montessuit,Sandra Lauper,Kinsey Maundrell,Bruno Antonsson,Jean-Claude Martinou +8 more
TL;DR: The results suggest that, during certain types of apoptosis, Bid translocates to mitochondria and binds to Bax, leading to a change in conformation of Bax and to cytochrome c release from mitochondria.
Journal ArticleDOI
Catalytic Activation of the Phosphatase MKP-3 by ERK2 Mitogen-Activated Protein Kinase
Montserrat Camps,Anthony Nichols,Corine Gillieron,Bruno Antonsson,Marco Muda,Christian Chabert,Ursula Boschert,Steve Arkinstall +7 more
TL;DR: Another homologous but nonselective phosphatase, MKP-4, bound and was activated by ERK2, JNK/SAPK, and p38 MAP kinases and was resistant to enzymatic inactivation by MKP.
Journal ArticleDOI
Cellular imaging in drug discovery
TL;DR: This review describes how cellular imaging technologies contribute to the drug discovery process and addresses both high-content and high-throughput needs.
Journal ArticleDOI
Furan-2-ylmethylene Thiazolidinediones as Novel, Potent, and Selective Inhibitors of Phosphoinositide 3-Kinase γ
Vincent Pomel,Jasna Klicic,David Covini,Dennis D. Church,Jeffrey P. Shaw,Karen Roulin,Fabienne Burgat-Charvillon,Delphine Valognes,Montserrat Camps,Christian Chabert,Corinne Gillieron,Bernard Françon,Dominique Perrin,Didier Leroy,Denise Gretener,Anthony Nichols,Pierre Alain Vitte,Susanna Carboni,Christian Rommel,Matthias Schwarz,Thomas Rückle +20 more
TL;DR: A novel series of furan-2-ylmethylene thiazolidinediones as selective, ATP-competitive PI3Kgamma inhibitors are disclosed and Compound 26 (AS-252424), a potent and selective small-molecule PI3kgamma inhibitor emerging from these efforts, was further profiled in three different cellular PI 3K assays and shown to be selective for class IB PI2K-mediated cellular effects.
Journal ArticleDOI
Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.
Pascale Gaillard,Isabelle Jeanclaude-Etter,Vittoria Ardissone,Steve Arkinstall,Yves Cambet,Montserrat Camps,Christian Chabert,Dennis Church,Rocco Cirillo,Denise Gretener,Serge Halazy,Anthony Nichols,Cedric Szyndralewiez,Pierre-Alain Vitte,Jean-Pierre Gotteland +14 more
TL;DR: The in vitro and in vivo anti-inflammatory potential of this new JNK inhibitor was investigated and found to demonstrate efficacy per oral route in an experimental model of rheumatoid arthritis (RA).